Abstract 2202
Background
Chemotherapy-induced temporary hair loss is one of the most common and distressing side-effects of cancer therapy. Scalp cooling is a long known method to reduce chemotherapy-induced alopecia in cancer patients, especially when antracycline or taxanes are used. However scalp cooling to reduce hair loss is still a controversial issue.
Methods
We included 210 breast cancer patients receiving chemotherapy both in (neo) adjuvant and palliative setting. Evaluation was focused on the quantification of chemotherapy-induced alopecia (CIA), satisfaction and side effects of the scalp cooling system. the severity of hair loss was assessed according to CTCAE version 4.0 by the nurses team together with the patient. Nurses completed questionnaires on patients baseline characteristics and type of chemotherapy received during each session of scalp-cooling The following chemotherapeutic treatments were included: doxorubicin alone or in combination with cyclophosphamide (AC); AC followed by paclitaxel,paclitaxel alone; FEC ; FEC followed by docetaxel.
Results
The mean overall success rate of scalp cooling (<50% hair loss) was at 62%. In the final results, major hair loss was avoided in 85% patients given taxane treatment, in 79% of patients given FEC treatment and in 32% of patients given AC treatment. None of these patients needed to use a wig and all of them were satisfied about the results at the final evaluation. 87% of the patients considered the avoidance of hair loss to be important before starting the chemotherapy. 12 patients discontinued scalp cooling for side-effects or low compliance.
Conclusions
Nurse team were properly trained and provided with higher experience; a standardized approach was used by the nurse staff for each patient with dedicated time. Our experience showed that scalp cooler provides a good chance for breast cancer patients to keep their hair during anthracyclines and/or taxane containing (neo-)adjuvant chemotherapy and could be integrated into daily practice of chemotherapy unit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabrizio Artioli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract